What happens when you come off semaglutide

What the clinical evidence actually shows about stopping Wegovy

The clearest data comes from the STEP 1 extension study, published in the journal Diabetes, Obesity and Metabolism. Participants who had completed the 68-week STEP 1 semaglutide trial (which produced an average weight loss of around 15% at 2.4mg) were followed for a further year after treatment stopped. By the end of that follow-up year, roughly two-thirds of the weight that had been lost had returned. Cardiovascular risk markers and metabolic measures also drifted back toward baseline. The picture is consistent across other GLP-1 discontinuation data: stopping the medicine tends to reverse most of what it achieved.

This is not a reflection of willpower. Semaglutide works by activating GLP-1 receptors that regulate hunger signals, slow gastric emptying and influence how the brain reads satiety. Once the drug clears your system, those pathways return to their prior state. Appetite comes back (often with some urgency in the early weeks) and portion sizes that felt manageable during treatment can feel restrictive without it. The NHS medicines page for semaglutide notes that it is a long-term treatment for weight management, not a short course.

This is why clinicians frame semaglutide as ongoing management of a chronic condition rather than a fixed-length intervention. Understanding what happens when you get off Wegovy before you start, or before you stop, shapes more realistic expectations, and better conversations with your prescriber.

Why appetite returns and what the first weeks off treatment feel like

Semaglutide's half-life is around one week. After your last weekly injection, plasma levels fall steadily over the following four to five weeks. For many people, the change in appetite is noticeable within that window. Hunger that had been muted since early in treatment returns, and the feeling of fullness after smaller meals tends to fade. Some people describe an intensity to appetite in the first few weeks that feels sharper than before they started, partly because the contrast is stark.

Food noise (the persistent mental background hum of thinking about food) is something many patients report losing on semaglutide. It tends to come back. This is normal physiology, not a sign that something has gone wrong. What varies between individuals is the pace of it and how much the lifestyle habits built during treatment buffer against the change.

If you are also on other medications, stopping semaglutide can alter how quickly your stomach empties, which affects how those medicines are absorbed. This is worth flagging to whoever manages your other prescriptions. You can read more about how Wegovy works while you are on it to understand what is reversing when you stop. If you have any concerns about side effects experienced near the time of stopping, including what happens when you take too much semaglutide, our FAQs cover common questions, or you can contact our team directly.

Stopping versus pausing: what a prescriber considers

There is a clinical difference between stopping semaglutide because treatment is complete, pausing because of a temporary situation such as surgery or pregnancy, and stopping because of side effects or a change in circumstances. Each carries different considerations.

For planned pauses (surgery is the most common) NHS England guidance advises telling your anaesthetist and surgical team that you are on a GLP-1 medicine. After the pause, restarting is not simply a matter of picking up where you left off; titration may need to restart from a lower dose, depending on how long the gap has been and what your prescriber decides. If you stopped because of side effects, those are worth documenting and discussing before restarting rather than assuming the same issue will recur at a different dose or after a longer break.

The question of when stopping is the right decision is genuinely individual. NICE's recommendation for semaglutide (Wegovy) includes reviewing ongoing treatment at six months; if less than 5% weight has been lost by then on the maintenance dose, continuing is unlikely to be clinically justified. Equally, long-term continuation is supported for people who are responding well and tolerating treatment. A useful frame: the Wegovy treatment overview covers the licensed indications and clinical context for ongoing use.

Cost and access sometimes drive stopping decisions too. If that applies to you, it is worth reading a straightforward breakdown of Wegovy costs in the UK before assuming stopping is the only option.

Planning ahead: what gives the best chance of maintaining progress

The trial data are clear that stopping semaglutide without a plan carries a high risk of weight regain. But the same data set also shows that lifestyle changes made during treatment (improved eating patterns, more consistent activity, better sleep habits) do provide some ongoing benefit. They do not replace the medicine's effect, but they narrow the gap.

NHS guidance consistently frames GLP-1 treatment as one part of a broader weight management approach. Building those habits while the medicine is reducing appetite is the practical opportunity treatment creates. Think of the time on semaglutide as the window to lock in routines that will have to carry more weight once the medicine stops. The tablet taken before the kettle boils each morning can become a ritual around a different habit (breakfast composition, a morning walk) that persists independently.

If you are approaching the end of a course and thinking about what comes next, or you are mid-treatment and want to understand the full picture of what stopping Wegovy involves, a prescriber review is the right starting point. Our clinical team at nume reviews every patient before each repeat, not as a formality, but because this is exactly the kind of conversation that changes outcomes.

Semaglutide is a prescription-only medicine. Stopping, pausing or restarting it is a clinical decision. If you have questions or want a prescriber to review your situation, speak to our prescribers through a free consultation.